Your email has been successfully added to our mailing list.

×
0 0 0 0 0.00542034222552877 -0.00143479647146355 0.00276331172281856 0.00488893612498665
Stock impact report

Cerecor restarts early-stage CERC-002 study in Crohn’s disease [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
Company Research Source: Seeking Alpha
Cerecor(NASDAQ:CERCresumedTop line data are expected in Q1 2021.CERC-002 is a fully human anti-LIGHT (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd. It offers the potential to treat cytokine release syndrome-induced COVID-19 ARDS in the near term and broader ARDS indication beyond. Show less Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
KNBWY alerts

from News Quantified
Opt-in for
KNBWY alerts

from News Quantified